Market Closed -
London S.E.
11:35:20 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
1.55
GBX
|
-6.06%
|
|
+26.53%
|
-76.87%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
35.51
|
209.8
|
74.69
|
96.06
|
18.29
|
12.12
|
12.12
|
-
|
Enterprise Value (EV)
1 |
25.73
|
205.7
|
71.78
|
84.1
|
18.29
|
17.68
|
32.73
|
31.76
|
P/E ratio
|
-15.3
x
|
-22.4
x
|
-31.8
x
|
-4.94
x
|
-0.41
x
|
-0.39
x
|
-0.75
x
|
55.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.99
x
|
292
x
|
7.19
x
|
63.2
x
|
4.09
x
|
0.98
x
|
0.33
x
|
0.17
x
|
EV / Revenue
|
2.17
x
|
286
x
|
6.91
x
|
55.4
x
|
4.09
x
|
1.43
x
|
0.9
x
|
0.45
x
|
EV / EBITDA
|
-9.14
x
|
-32.1
x
|
130
x
|
-4.74
x
|
-0.78
x
|
-0.75
x
|
-2.67
x
|
1.57
x
|
EV / FCF
|
-
|
-38
x
|
-50.4
x
|
-4.92
x
|
-
|
-0.6
x
|
-2.44
x
|
6.11
x
|
FCF Yield
|
-
|
-2.63%
|
-1.98%
|
-20.3%
|
-
|
-166%
|
-41%
|
16.4%
|
Price to Book
|
-
|
-
|
2.47
x
|
2.34
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
116,426
|
117,189
|
117,620
|
215,874
|
259,388
|
782,056
|
782,056
|
-
|
Reference price
2 |
0.3050
|
1.790
|
0.6350
|
0.4450
|
0.0705
|
0.0155
|
0.0155
|
0.0155
|
Announcement Date
|
4/3/19
|
5/21/20
|
4/29/21
|
6/30/22
|
4/27/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
11.88
|
0.719
|
10.39
|
1.519
|
4.467
|
12.36
|
36.29
|
71.12
|
EBITDA
1 |
-2.814
|
-6.414
|
0.551
|
-17.74
|
-23.34
|
-23.64
|
-12.28
|
20.2
|
EBIT
1 |
-5.168
|
-9.035
|
-2.154
|
-19.95
|
-25.71
|
-23.82
|
-13.83
|
4.938
|
Operating Margin
|
-43.5%
|
-1,256.61%
|
-20.74%
|
-1,313.5%
|
-575.46%
|
-192.69%
|
-38.11%
|
6.94%
|
Earnings before Tax (EBT)
1 |
-5.153
|
-9.066
|
-1.886
|
-19.56
|
-40.08
|
-26.24
|
-16.18
|
14.9
|
Net income
1 |
-1.794
|
-8.8
|
-2.63
|
-19.34
|
-40.44
|
-27
|
-10.9
|
11.8
|
Net margin
|
-15.1%
|
-1,223.92%
|
-25.32%
|
-1,272.94%
|
-905.4%
|
-218.42%
|
-30.04%
|
16.59%
|
EPS
2 |
-0.0200
|
-0.0800
|
-0.0200
|
-0.0900
|
-0.1700
|
-0.0398
|
-0.0207
|
0.000280
|
Free Cash Flow
1 |
-
|
-5.416
|
-1.423
|
-17.11
|
-
|
-29.37
|
-13.42
|
5.198
|
FCF margin
|
-
|
-753.27%
|
-13.7%
|
-1,126.4%
|
-
|
-237.6%
|
-36.99%
|
7.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
25.73%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
44.05%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/3/19
|
5/21/20
|
4/29/21
|
6/30/22
|
4/27/23
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2022 S1
|
2023 S1
|
---|
Net sales
1 |
8.919
|
2.031
|
4.334
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-11.72
|
-11.54
|
Operating Margin
|
-
|
-577.25%
|
-266.29%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
9/16/20
|
9/8/22
|
9/28/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
5.55
|
20.6
|
19.6
|
Net Cash position
1 |
9.78
|
4.1
|
2.91
|
12
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.235
x
|
-1.679
x
|
0.9724
x
|
Free Cash Flow
1 |
-
|
-5.42
|
-1.42
|
-17.1
|
-
|
-29.4
|
-13.4
|
5.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-8.43%
|
-54.2%
|
-
|
-
|
-
|
131%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
0.2600
|
0.1900
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-0
|
-0.0300
|
-0.0100
|
-0.0800
|
-
|
-0.0500
|
-0.0200
|
0.0200
|
Capex
1 |
3
|
1.35
|
0.02
|
0.37
|
-
|
0.94
|
0.7
|
0.74
|
Capex / Sales
|
25.24%
|
187.76%
|
0.22%
|
24.49%
|
-
|
7.63%
|
1.94%
|
1.04%
|
Announcement Date
|
4/3/19
|
5/21/20
|
4/29/21
|
6/30/22
|
4/27/23
|
-
|
-
|
-
|
Last Close Price
0.0155
GBP Average target price
0.02
GBP Spread / Average Target +29.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -76.87% | 16.12M | | -1.43% | 103B | | +8.96% | 101B | | +4.40% | 23.07B | | -12.15% | 22.23B | | -4.36% | 18.05B | | -39.98% | 17.18B | | -10.04% | 16.94B | | +6.79% | 14.07B | | +38.61% | 12.35B |
Bio Therapeutic Drugs
|